DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/04/3208-794-799$20.00
DMD 32:794-799, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hilmer, S. N.
Right arrow Articles by Le Couteur, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilmer, S. N.
Right arrow Articles by Le Couteur, D. G.

THE HEPATIC PHARMACOKINETICS OF DOXORUBICIN AND LIPOSOMAL DOXORUBICIN

Sarah N. Hilmer, Victoria C. Cogger, Michael Muller, and David G. Le Couteur

Centre for Education and Research on Ageing and ANZAC Research Institute, University of Sydney, Concord RG Hospital, Sydney, Australia

To determine the role of the hepatic sinusoidal endothelium in the hepatic disposition of liposomal doxorubicin, we compared the hepatic pharmacokinetics of doxorubicin hydrochloride and the pegylated, liposomal formulation of doxorubicin (Caelyx). The multiple indicator-dilution technique and electron microscopy were used to study the disposition of doxorubicin and liposomal doxorubicin in the rat liver. Doxorubicin had a volume of distribution 1.56 ± 0.45 times greater than that of the extracellular marker, sucrose, whereas liposomal doxorubicin had a volume of distribution 0.56 ± 0.30 times smaller than that of sucrose (P < 0.001). The recovery of doxorubicin was less than that of liposomal doxorubicin (70 ± 24% versus 94 ± 17%, P < 0.05). The disposition of liposomal doxorubicin was found to be flow-limited, whereas a permeability-limited sequestration model fitted doxorubicin. The transfer of doxorubicin across the hepatocyte membrane was symmetrical (permeability - surface area product for influx 0.02 ± 0.01 ml s/g versus 0.03 ± 0.02 ml s/g for efflux) and consistent with diffusion. Electron microscopy confirmed that liposomes were restricted entirely to the sinusoidal lumen and none were seen in the extracellular space of Disse. Liposomal doxorubicin is restricted to the sinusoidal lumen, presumably secondary to steric exclusion by fenestrations in the sinusoidal endothelium. This provides the mechanism for the longer half-life and reduced hepatic extraction of liposomal doxorubicin compared with doxorubicin. The sinusoidal endothelium and fenestrations within the sinusoidal endothelium have an important role in hepatic pharmacology and are important considerations when designing liposomal preparations.

Address correspondence to: David G. Le Couteur, Centre for Education and Research on Ageing, Concord Hospital, Hospital Road, NSW 2139 Australia. E-mail: dlecouteur{at}med.usyd.edu.au




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
L. Smith, M. B. Watson, S. L. O'Kane, P. J. Drew, M. J. Lind, and L. Cawkwell
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays.
Mol. Cancer Ther., August 1, 2006; 5(8): 2115 - 2120.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.